乌苯美司胶囊联合DP方案治疗非小细胞肺癌临床观察

Clinical effectiveness of ubenimex plus taxotere and cisplatin in the treatment of advanced non-small-cell lung cancer

目的评价乌苯美司胶囊联合多西紫杉醇和顺铂(DP)方案治疗晚期非小细胞肺癌患者临床疗效和不良反应。方法经病理证实为Ⅲ_b～Ⅳ期非小细胞肺癌60例患者随机分成两组,对照组予DP方案化疗,试验组DP方案化疗基础上加服3个月乌苯美司胶囊,每位患者完成至少3个周期化疗,观察两组外周血有核细胞CD4/CD8、总生存时间、化疗的不良反应。结果试验组在服用乌苯美司胶囊后较对照组CD4/CD8比值显著提高(P<0.05)。两组客观疗效(CR+PR)无显著性差异(P>0.05),分别为36.0%和43.3%;总生存时间试验组较对照组显著延长(P均<0.05)。白细胞减少的发生率试验组较对照组有显著下降(P<0.05)。结论非小细胞肺癌DP方案化疗患者服用乌苯美司胶囊后虽客观疗效无显著差异,但可显著提高机体免疫功能,延长总生存时间,降低化疗不良反应。

Objective To evaluate the clinical efficacy and toxicity of ubenimex plus taxotere and cisplatin （DP） in the treatment of advanced non-small-cell lung cancer （NSCLC）. Methods Sixty patients with advanced NSCLC were egually randomized into two groups ： control group （ administered with DPonly ） and ubenimex group （ DPplus ubenim- ex）. All patients were treated for at the least 3 cycles. The CD4/CD8 ratio, overall survival, and adverse events were determined and observed. Results The CD4/CD8 ratio increased markedly in ubenimex group compared with control group （ P 〈 0. 05 ）. Comprared to the control group, the overall survival in ubenimex group significantly prolonged （ P 〈 0. 05）. Conclusions Ubenimex may strengthen the immune function, prolong the overall survival time, and decrease treatment-associated adverse events.